TY - JOUR
T1 - High incidence of high-risk HPV in benign and malignant lesions of the larynx
AU - Duray, Anaëlle
AU - Descamps, Géraldine
AU - Arafa, Mohammad
AU - Decaestecker, Christine
AU - Remmelink, Myriam
AU - Sirtaine, Nicolas
AU - Ernoux-Neufcoeur, Perle
AU - Mutijima, Eugène
AU - Somja, Joan
AU - Depuydt, Christophe E
AU - Delvenne, Philippe
AU - Saussez, Sven
PY - 2011/7
Y1 - 2011/7
N2 - The aim of this study was to determine the prevalence of human papillomavirus (HPV) in patients with laryngeal benign lesions (LBLs) and laryngeal squamous cell carcinomas (LSCCs) using a sensitive E6/E7 type-specific PCR. Paraffin-embedded samples from LBL (n=39) and LSCC patients (n=67) were evaluated for the presence of HPV DNA by GP5+/GP6+ consensus PCR and E6/E7 type-specific PCR for HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68. In LSCCs, immunohistochemical staining of p16, p53 and EGFR was also assessed. The E6/E7 type-specific PCR showed that 44 out of 59 LSCC patients (i.e., 75%) had high-risk (hr) HPV types and that 27 out of 35 LBL patients (i.e., 77%) had hrHPV types. HPV-16 viral load was significantly higher in LSCC than in LBL patients (p<10-6). The presence of hrHPV DNA did not correlate with the proportion of disease-free patients. Comparable levels of p16, p53 and EGFR expression were observed in the hrHPV+ tumor group (100% p16+, 56% p53+ and 97% EGFR+) and in the HPV- or low-risk (lr) HPV+ tumor group (92% p16+, 66% p53+ and 100% EGFR+). A very high prevalence of oncogenic HPV-16 was found in a series of benign and malignant laryngeal lesions. LSCC appears to be characterized by an active hrHPV infection. In LSCCs, the hrHPV+ subgroup had a similar prognosis (in terms of risk of recurrence) as the HPV- subgroup.
AB - The aim of this study was to determine the prevalence of human papillomavirus (HPV) in patients with laryngeal benign lesions (LBLs) and laryngeal squamous cell carcinomas (LSCCs) using a sensitive E6/E7 type-specific PCR. Paraffin-embedded samples from LBL (n=39) and LSCC patients (n=67) were evaluated for the presence of HPV DNA by GP5+/GP6+ consensus PCR and E6/E7 type-specific PCR for HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68. In LSCCs, immunohistochemical staining of p16, p53 and EGFR was also assessed. The E6/E7 type-specific PCR showed that 44 out of 59 LSCC patients (i.e., 75%) had high-risk (hr) HPV types and that 27 out of 35 LBL patients (i.e., 77%) had hrHPV types. HPV-16 viral load was significantly higher in LSCC than in LBL patients (p<10-6). The presence of hrHPV DNA did not correlate with the proportion of disease-free patients. Comparable levels of p16, p53 and EGFR expression were observed in the hrHPV+ tumor group (100% p16+, 56% p53+ and 97% EGFR+) and in the HPV- or low-risk (lr) HPV+ tumor group (92% p16+, 66% p53+ and 100% EGFR+). A very high prevalence of oncogenic HPV-16 was found in a series of benign and malignant laryngeal lesions. LSCC appears to be characterized by an active hrHPV infection. In LSCCs, the hrHPV+ subgroup had a similar prognosis (in terms of risk of recurrence) as the HPV- subgroup.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Carcinoma, Squamous Cell/complications
KW - Child
KW - Cyclin-Dependent Kinase Inhibitor p16
KW - ErbB Receptors/metabolism
KW - Female
KW - Human papillomavirus 16/genetics
KW - Humans
KW - Incidence
KW - Laryngeal Neoplasms/complications
KW - Male
KW - Middle Aged
KW - Neoplasm Proteins/metabolism
KW - Papillomaviridae/genetics
KW - Papillomavirus Infections/complications
KW - Prognosis
KW - Survival Analysis
KW - Tumor Suppressor Protein p53/metabolism
KW - Viral Load
KW - Young Adult
U2 - 10.3892/ijo.2011.1031
DO - 10.3892/ijo.2011.1031
M3 - Article
C2 - 21573490
SN - 1019-6439
VL - 39
SP - 51
EP - 59
JO - International Journal of Oncology
JF - International Journal of Oncology
IS - 1
ER -